Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01110473 · ClinicalTrials.gov registry record · Phase 1
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
A Phase 1 study of Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 3
- Study locations
NCT01110473: Completed Phase 1 study of Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia, sponsored by AbbVie (prior sponsor, Abbott).
NCT01110473 is a Phase 1 study of Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 52 participants, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01110473, a Phase 1 study of Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the safety, pharmacokinetics and maximum tolerated dose of ABT-348 as monotherapy and when given in combination with azacitidine.
Conditions Studied
Interventions
- DRUG ABT-348
- DRUG ABT-348 and azacitidine
Study Locations (3)
Arizona
- Site Reference ID/Investigator# 59324 - Scottsdale
Georgia
- Site Reference ID/Investigator# 26523 - Atlanta
Texas
- Site Reference ID/Investigator# 26522 - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-04 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
What the finished NCT01110473 record still lists
NCT01110473 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (86% lower).
The record links to 5 conditions, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which ABT-348 is the first listed.
NCT01110473 reports a single indexed study location in Arizona, Georgia, Texas.
Frequently Asked Questions
What is clinical trial NCT01110473 about?
NCT01110473 is a clinical study titled "ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies". The purpose of this study is to determine the safety, pharmacokinetics and maximum tolerated dose of ABT-348 as monotherapy and when given in combination with azacitidine.
What is the current status of trial NCT01110473?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2010-04. Estimated completion is 2013-06.
What conditions does trial NCT01110473 study?
This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, B-cell Chronic Lymphocytic Leukemia.
What interventions are being tested in trial NCT01110473?
The interventions under investigation include: ABT-348 (DRUG), ABT-348 and azacitidine (DRUG).
Who is sponsoring clinical trial NCT01110473?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01110473 being conducted?
This trial has 3 study locations across Arizona, Georgia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01110473's enrollment target sits among peer trials
52 70th of 131 higher than 61 of 131 other Acute Lymphoblastic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Lymphoblastic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
RECRUITING · Phase 1
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
RECRUITING · Phase 1
-
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia